Al­ny­lam sues Mod­er­na and Pfiz­er again over Covid-19 vac­cine patent in­fringe­ment

The patent bat­tle over Covid-19 vac­cine de­liv­ery tech­nol­o­gy in­ten­si­fied yes­ter­day af­ter Al­ny­lam Phar­ma­ceu­ti­cals yet again ac­cused Mod­er­na and Pfiz­er of vi­o­lat­ing patents.

In two sep­a­rate law­suits filed Tues­day, Al­ny­lam said that the vac­cine mak­ers in­fringed on its patent re­lat­ing to lipid nanopar­ti­cle tech­nol­o­gy that has been cen­tral to de­liv­er­ing mR­NA in­to hu­man cells.

“The Al­ny­lam LNP Tech­nol­o­gy is foun­da­tion­al to the suc­cess of the re­cent­ly de­vel­oped mes­sen­ger RNA (‘mR­NA’) based COVID vac­cines,” ac­cord­ing to the law­suits filed in Delaware fed­er­al court.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER